Therapeutic options in neuromyelitis optica spectrum disorders

Expert Rev Neurother. 2016;16(3):319-29. doi: 10.1586/14737175.2016.1150178.

Abstract

Neuromyelitis optica is a relapsing inflammatory disorder of the central nervous system that manifests predominantly with attacks of optic neuritis and longitudinally extensive transverse myelitis; attacks are often severe. In contrast to multiple sclerosis, a secondary progressive phase is rare, and disability in neuromyelitis optica spectrum disorders is related to relapses. Thus, prompt and effective treatment of relapses, and early initiation of long-term immunosuppression to prevent subsequent attacks is required in order to prevent morbidity and mortality.

Keywords: AQP4-Ab; NMO; NMOSD; Neuromyelitis optica; aquaporin-4; neuromyelitis optica spectrum disorders; treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Neuromyelitis Optica / therapy*

Substances

  • Immunosuppressive Agents